Zinc acetate complex with 3-hydroxypyridine with anti-hypoxic activity under conditions of acute exogenous hypoxia

FIELD: pharmacology.

SUBSTANCE: invention relates to a zinc acetate complex with 3-hydroxypyridine of the formula: .

EFFECT: metal complex has antihypoxic activity under conditions of acute exogenous hypoxia.

1 tbl

 



 

Same patents:

FIELD: electricity.

SUBSTANCE: invention relates to the electroluminescent device. The device contains hole injecting layer, hole transport layer, electronic block layer, active luminescent layer based on luminescent substance, hole-block layer, electronic transport layer, electronic injecting layer. As the luminescent substance it contains bis[2-(N-tosylamino)-benzylidene-2-aminopyridinato] of zinc (II) of formula I: .

EFFECT: electroluminescent device based on chelate complexes of zinc of azometin derivants 2-(N-tosylaminobenzaldehyde), emitting in yellow-green spectrum.

6 dwg, 1 tbl, 1 ex

FIELD: chemistry.

SUBSTANCE: invention relates to chemistry and chemical technology, namely to synthesis of modified silicagels, containing molecules of substituted phthalocyanines covalently bound with them, and their application for water photoremediation. Method of water photoremediation with application of radiation of visible range in presence of oxygen and heterogenic sensibiliser of general formula: , where R=H is either SPh; X is anion; n=4-8; M=Zn, AlL, GaL, SiLz; L=Cl, OH; M=1-4.

EFFECT: invention makes it possible to carry out efficient purification of water from bacteriological contamination.

2 cl, 3 tbl, 11 ex

FIELD: chemistry.

SUBSTANCE: invention relates to zinc complexes of 5-[2-hydroxy(tosylamino)benzylidene-amino]-2-(2-tosylaminophenyl)-1-alkylbenzimidazoles of general formula I , where R = alkyl C1-C6; X=O, ; .

EFFECT: compounds I exhibit luminescent properties and can be used as luminophores for producing organic light-emitting diodes emitting white and visible light.

18 ex

FIELD: chemistry.

SUBSTANCE: invention relates to novel metal chelates, namely to zinc and cadmium complexes of tetradentate azomethines of 2-tosylaminebenzaldehyde and dioxydiamines of formula I , where m=2-4, n=2-4, M=Zn, Cd.

EFFECT: metal-complex compounds I demonstrate photoluminiscent properties in the blue spectrum region and can be used as an electroluminescent layer in the creation of organic light-emitting diodes (OLED) of white and visible light.

4 cl, 5 ex

FIELD: chemistry.

SUBSTANCE: claimed is a silicon-zinc-containing glycerohydrogel, possessing a wound healing, regenerative and antibacterial activity, a composition of which corresponds to formula kSi(C3H7O3)4·ZnC3H6O3·xC3H8O3·yH2O, where 1≤k≤4, 7≤x≤26, 20≤y≤100, obtained by interaction of tetraglycerolate of silicon in excess of glycerol Si(C3H7O3)4·xC3H8O3, where 0,5≤x≤10, monoglycerolate of zinc in abundance of glycerol ZnC3H6O3·6C3H8O3 and water in molar ratio Si(C3H7O3)4:ZnC3H6O3:C3H8O3:H2O equal to (1÷4):1:(7÷26):(20÷100) at a temperature of 20-40°C and intensive mixing.

EFFECT: claimed silicon-zinc-containing glycerohydrogel possesses the wound healing, regenerative and antibacterial activity, is simple to obtain and convenient in application.

1 tbl, 6 ex

FIELD: chemistry.

SUBSTANCE: invention relates to novel compounds in a series of chelate complexes of zinc with azomethine derivatives, namely to bis[2-(N-tozylamino)benzyliden-4'-dimethylaminophenyliminato]zinc(II) of formula I Also claimed is electroluminescent device.

EFFECT: invention makes it possible to obtain compounds, demonstrating electroluminescent properties with high brightness.

2 cl, 3 dwg, 1 tbl, 2 ex

FIELD: chemistry.

SUBSTANCE: described are 15-crown-5- and dithia-18-crown-6-containig 2-methyl-9-styryl phenanthrolines of formula: where as optical sensors on cations of calcium, barium and lead. Claimed compounds are obtained by interaction of ligand of 15-crown-5 or dithia-18-crown-6-containing 2-methyl-9-styryl phenanthroline with zinc perchlorate in acetonitrile with irradiation with red light.

EFFECT: complexes possess properties of highly efficient fluorescent sensors on cations of calcium, barium and lead, which make it possible to visually determine metal cation.

2 cl, 2 tbl, 2 ex

FIELD: chemistry.

SUBSTANCE: invention relates to zinc complex of asymmetric ethylenediamine-N,N-dipropyonic acid dichloride of formula Also claimed is method of its obtaining. Complex can be applied for solution of problems, associated with the necessity to introduce Zn2+ in chelate form instead of its mineral salts, as well as to serve as initial product for synthesis of other chemical compounds of series of polydentate ligands, in particular asymmetric ethylenediamine-N,N-dipropyonic acid.

EFFECT: obtaining zinc complex of asymmetric ethylenediamine-N,N-dipropyonic acid dichloride.

4 cl, 4 dwg, 3 ex

FIELD: biotechnologies.

SUBSTANCE: invention refers to a compound having general formula (I),

where: m and n are independent integer numbers of 1 to 6; each of X1-X3 and Y1-Y3 is O; each of R1-R3 is independently chosen from a group consisting of hydrogen or alkyl; and R is O-(CH2)x-C(-O)NR'-(CH2)y-NHR'. Besides, x and y are independent integer numbers of 1 to 6; and R' is chosen from the group consisting of hydrogen and alkyl. In addition, an antibody containing an antigen recognition area, use of the compound, pharmaceutical composition, use of the antibody, method for MMP-2 or MMP-9 activity inhibition in a sample and a composition for determining MMP-2 or MMP-9 are proposed.

EFFECT: invention allows obtaining compounds that are able to inhibit MMP-2 or MMP-9 activity.

11 cl, 16 dwg, 4 tbl, 11 ex

FIELD: chemistry.

SUBSTANCE: invention relates to molecular complexes of zinc and cadmium bis(1-phenyl-3-methyl-4-formyl-5-pyrazolonate) with amino-derivatives of nitric heterocycles of general formula (I) (NH2-Het)n, where NH2-Het is 1-aminoisoquinoline, 3-aminoquinoline, 6-aminoquinoline, 5-amino-4,6-dimethylquinoline, 2-aminopyridine, 2-amino-5-bromopyridine, 3-amino-5-methylisoxazole, 2-amino-1-ethylbenzimidazole, M is Zn, Cd, n=1, 2.

EFFECT: molecular complexes of formula (I) exhibit luminescent properties in the blue region of the spectrum and can be used as phosphors for making organic light-emitting diodes of white and visible light.

14 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to new phenylamide or pyridylamide derivatives of formula

or their acceptable salts, wherein A1 is CR12 or N; A2 is CR13 or N; R1 and R2 are independently specified in hydrogen, C1-7-alkyl, halogen and C1-7-alkoxygroup; R12 and R13 are independently specified in hydrogen, C1-7-alkyl, halogen, C1-7-alkoxygroup, amino group and C1-7-alkylsulphanyl; R3 is specified in hydrogen, C1-7-alkyl, halogen, C1-7-alkoxygroup, cyano group, C3-7-cycloalkyl, five-merous heteroaryl and phenyl; R4 is specified in methyl and ethyl; or R3 and R4 together represent -X-(CR14R15)n- and form a part of the ring, wherein X is specified in -CR16R17-, O, S, C=O; R14 and R15 are independently specified in hydrogen or C1-7-alkyl; R16 and R17 are independently specified in hydrogen, C1-7-alkoxycarbonyl, heterocyclyl substituted by two groups specified in a halogen, or R16 and R17 together with an atom C, which they are attached to, form =CH2 group; or X is specified in a group NR18; R14 and R15 are hydrogen; R18 is specified in hydrogen, C1-7-alkyl, halogen-C1-7-alkyl, C3-7-cycloalkyl, C3-7-cycloalkyl-C1-7-alkyl, heterocyclyl, heteroaryl-C1-7-alkyl, carboxyl-C1-7-alkyl, C1-7-alkoxycarbonyl-C1-7-alkyl, C1-7-alkylcarbonyloxy-C1-7-alkyl, phenyl, wherein phenyl is unsubstituted, phenylcarbonyl, wherein phenyl is substituted by C1-7-alkoxycarbonyl, and phenylsulphonyl, wherein phenyl is substituted by carboxyl-C1-7-alkyl, or R18 and R14 together represent -(CH2)3- and form a part of the ring, or R18 together with R14 and R15 represent -CH=CH-CH= and form a part of the ring; and n has the value of 1, 2 or 3; B1 represents N or CR19 and B2 represents N or CR20, provided no more than one of B1 and B2 represents N; and R19 and R20 are independently specified in a group consisting of hydrogen and halogen-C1-7-alkyl; R5 and R6 are independently specified in a group consisting of hydrogen, halogen and cyano group; and one-three, provided R4 represents methyl or ethyl, two of the residues R7, R8, R9, R10 and R11 are specified in C1-7-alkyl, halogen, halogen-C1-7-alkyl, halogen-C1-7-alkoxygroup, cyano group, C1-7-alkoxycarbonyl, hydroxy-C3-7-alkynyl, carboxyl-C1-7-alkyl, carboxyl-C2-7-alkenyl, C1-7-alkoxycarbonyl-C2-7-alkenyl, C1-7-alkoxycarbonyl-C2-7-alkynyl, C1-7-alkoxycarbonyl-C1-7-alkylaminocarbonyl, carboxyl-C1-7-alkylaminocarbonyl-C1-7-alkyl, carboxyl-C1-7-alkyl-(C1-7-alkylamino)-carbonyl-C1-7-alkyl, phenyl-carbonyl, wherein phenyl is unsubstituted, phenyl-C1-7-alkyl, wherein phenyl is substituted by 1-2 groups specified in a halogen, C1-7-alkoxygroup, carboxyl, phenyl-C2-7-alkynyl, wherein phenyl is substituted by 2 groups specified in halogen, carboxyl or C1-7-alkoxycarbonyl, and pyrrolidine carbonyl-C1-7-alkyl, wherein pyrrolidinyl is substituted by carboxyl, and the other R7, R8, R9, R10 and R11 represent hydrogen; the term 'heteroaryl' means an aromatic 5-merous ring containing one or two atoms specified in nitrogen or oxygen; the term 'heterocyclyl' means a saturated 4-merous ring, which can contain one atom specified in nitrogen or oxygen. Besides, the invention refers to a pharmaceutical composition based on the compound of formula I.

EFFECT: there are prepared new compounds possessing the GPBAR1 agonist activity.

21 cl, 1 tbl, 190 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to a new compound of formula [I] or to its pharmaceutically acceptable salt, wherein A represents optionally substituted alkyl, wherein the substitute represents identical or different 1-3 groups specified in aryl optionally substituted by 1-3 groups specified in alkyl, halogen, alkoxy and alkanoyl; cycloalkyl optionally substituted by 1-3 groups specified in alkyl and halogen; hydroxy; alkoxy; halogen; an amino group and oxo; an optionally substituted carbocyclic group specified in a mono- and bicyclic group, wherein an aromatic ring and cycloalkyl are condensed; optionally substituted aryl, an optionally substituted completely saturated 5- or 6-merous monocyclic heterocyclic group each of which contains 1 heteroatom specified in nitrogen and oxygen, wherein the substitute of optionally substituted aryl, the optionally substituted carbocyclic group and the optionally substituted heterocyclic group for A represents identical or different 1-3 groups specified in alkyl, optionally substituted hydroxy, alkoxy, cycloalkyl or halogen; cycloalkyl optionally substituted by alkyl or alkoxy; alkoxy optionally substituted by halogen; halogen; hydroxy; oxo; heterocycle; alkyl sulphonyl; and mono- or dialkylcarbamoyl, optionally substituted amino, wherein the substitute represents identical or different 1 or 2 alkyl or aryl, or optionally substituted carbamoyl, wherein the substitute represents identical or different 1 or 2 alkyls optionally substituted by aryl, X represents optionally substituted methylene or -O-, wherein the substitute of optionally substituted methylene for X represents alkoxy or hydroxy, Q represents N or C-R4, L1 represents a single bond, methylene, -CH=CH-, -O-, -CO-, -NR11-, -NR11CO-, -CONR11- or -CH2NR11-, L2 represents a single bond, -CR6R7- or a bivalent 5- or 6-merous completely saturated monocyclic heterocyclic group each of which contains 1 heteroatom specified in nitrogen and oxygen, R1 and R2 are identical or different, and each represents hydrogen, alkyl or halogen, R3 and R4 are identical or different, and each represents hydrogen, alkyl, alkoxy, cyano or halogen, R1 and R3 are optionally bond thereby forming 5- or 6-merous cycloalkane, or a 5- or 6-merous aliphatic heterocycle containing oxygen atom, R5 represents a carboxyl group, an alkoxycarbonyl group or a bioisosteric group of the carboxyl group, R6 and R7 are identical or different, and each represents hydrogen or alkyl, or R6 and R7 are bond thereby forming cycloalkane, R8 represents hydroxy, alkanoylamino or alkyl sulphonylamino, R9 and R10 represent hydrogen or halogen, and R11 represents hydrogen or alkyl. Besides, the invention refers to specific compounds of formula [I], a drug based on the compound of formula [I], using the compound of formula [I], a method of treating based on using the compound of formula [I], and an intermediate compound of formula [II].

EFFECT: there are prepared new compounds possessing the agonist activity on thyroid hormone β receptor.

18 cl, 36 tbl, 344 ex

FIELD: chemistry.

SUBSTANCE: invention relates to a stable liquid pharmaceutical composition, which includes 3-(2,2,2-trimethylhydrazinium)propionate-2-ethyl-6-methyl-3-hydroxypyridine disuccinate in amount of 0.1-50 wt %, auxiliary substances in amount of 0.01-50 wt % and water.

EFFECT: invention enables to obtain stable pharmaceutical compositions for injection, peroral and local application, having marked antihypoxic, antioxidant and adaptogenic action.

32 cl, 1 dwg, 14 tbl, 60 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to a new compound that is a complex of 3-(2,2,2-trimethylhydrazinium)propionate-2-ethyl-6-methyl-3-hydroxypyridinium disuccinate of formula: . Additionally, the invention refers to stable crystalline forms of the complex of 3-(2,2,2-trimethylhydrazinium)propionate-2-ethyl-6-methyl-3-hydroxypyridinium disuccinate, as well as to methods for preparing the above complexes.

EFFECT: what is prepared and characterised is the new compound which possesses antihypoxic and adaptogenic action, and also low toxicity and storage stability, and which can find application in medicine and veterinary science.

11 cl, 17 ex, 10 tbl, 4 dwg

FIELD: chemistry.

SUBSTANCE: invention relates to a salt of 2-ethyl-6-methyl-3-hydroxypyridine with nicotinic acid, a method of producing said salt, as well as a method of correcting metabolic disorders in case of sugar diabetes with diabetes with exogenous hypercholesteremia and morphofunctional disorders and brain during acute ischemia.

EFFECT: novel salt of 2-ethyl-6-methyl-3-hydroxypyridine with nicotinic acid is described, which has hypoglycemic, hypolipidemic and neuroprotective activity and can be used in endocrinology, cardiology, neurology, emergency treatment and intensive care.

4 cl, 3 ex

FIELD: chemistry.

SUBSTANCE: invention relates to a crystalline form of 2-ethyl-6-methyl-3-oxypyridine succinate which is stable during storage and a synthesis method thereof. Synthesis is carried out in water with molar ratio 2-ethyl-6-methyl-3-oxypyridine: succinic acid: water equal to (1:1.055-1.066:10-12) and the end product is extracted at temperature from 0 to +5°C.

EFFECT: stability of the obtained product during storage, absence of toxic impurities, method avoids use of toxic and inflammable organic solvents, which improves working conditions and prevents contamination of the environment and the working area.

7 cl, 21 ex, 9 dwg

FIELD: chemistry.

SUBSTANCE: invention refers to a new compound aspirinate 2-ethyl-6-methyl-3-hydroxipiridine with formula I: that is antihypoxic and to the way of its production that includes interaction between equimolar amounts of acetosalic acid and 2-ethyl-6-methyl-3-hydroxipiridine in the conditions of mechanochemical influence with the presence of an inert wetter.

EFFECT: new compound that may be applied in medicine, and more precisely in cardiology and neurology.

6 cl, 1 tbl, 10 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to compounds with common formulae I, II, IV and V: (I), (III), (IV), (V), values of radicals, such as provided in invention formula. Besides, proposed invention relates to pharmaceutical composition on the basis of above-described compounds, to their application, and also to method for treatment of repeated urination, incontinence and higher activity of urinary bladder, besides, to method to treat pain.

EFFECT: new compounds have been produced and described, which may be useful for treatment of diseases related to fatty-acid amide-hydrolase (FAAH), in particular to treat repeated urination and incontinence, higher activity of bladder and/or pain.

16 cl, 442 ex, 73 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to compounds with common formulae I, II, IV and V: (I), (III), (IV), (V), values of radicals, such as provided in invention formula. Besides, proposed invention relates to pharmaceutical composition on the basis of above-described compounds, to their application, and also to method for treatment of repeated urination, incontinence and higher activity of urinary bladder, besides, to method to treat pain.

EFFECT: new compounds have been produced and described, which may be useful for treatment of diseases related to fatty-acid amide-hydrolase (FAAH), in particular to treat repeated urination and incontinence, higher activity of bladder and/or pain.

16 cl, 442 ex, 73 tbl

FIELD: chemistry.

SUBSTANCE: invention describes compounds of formula (1) , where substitutes are as defined in paragraph 1 of the invention. The compounds have fungicide properties. The method of obtaining formula (1) compounds is described, in which n equals 0. Described also is a fungicide composition based on formula (1) compounds and a phytopathogenic fungus control method which uses compounds in paragraph 1 or a composition based on the said compounds.

EFFECT: obtaining novel compounds which can be used as fungicides.

24 cl, 312 tbl, 14 ex

FIELD: veterinary medicine.

SUBSTANCE: treatment is carried out with an aqueous solution of the preparation "Biopag-D" at a concentration of 4-2% by drifting animals through the baths with the solution having the immersion depth up to the carpal joint.

EFFECT: invention enables to treat efficiently and stress-free and prevent treatment of diseases of hooves and dew claws of animals.

3 cl, 5 dwg, 4 tbl, 1 ex

Up!